학술논문

85 - Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment.
Document Type
Abstract
Source
Leukemia Research. Apr2017 Supplement 1, Vol. 55, pS54-S54. 1p.
Subject
*MYELODYSPLASTIC syndromes treatment
*AZACITIDINE
*MYELODYSPLASTIC syndromes
*PATIENTS
*THERAPEUTICS
Language
ISSN
0145-2126